Revvity Inc (RVTY)

08:48 AM

Revvity (RVTY) Introduces New Mimix Standards for Improved IVD Testing | RVTY Stock News - GuruFocus

08:48 AM

08:00 AM

Revvity Introduces New IVD Reference Standards for Monitoring Oncology Diagnostic Testing Workflows - Business Wire

08:00 AM

May 30, 2025

Insider Sell: Michelle Mcmurry-heath Sells 600 Shares of Revvity Inc (RVTY) - GuruFocus

May 30, 2025

May 30, 2025

Does The Market Have A Low Tolerance For Revvity, Inc.'s (NYSE:RVTY) Mixed Fundamentals? - Yahoo

May 30, 2025

May 28, 2025

Shareholders in Revvity (NYSE:RVTY) are in the red if they invested three years ago - simplywall.st

May 28, 2025

May 27, 2025

Revvity Inc (RVTY) Shares Up 3.52% on May 27 - GuruFocus

May 27, 2025

May 25, 2025

RVTY Stock Falls Despite the Latest Launch of Automated Instrument - MSN

May 25, 2025

May 23, 2025

Revvity’s EUROIMMUN unveils new fully automated instrument for specialty testing - SelectScience

May 23, 2025

May 22, 2025

Enhancing Laboratory Efficiency with Revvity's IDS i20™ Platform - Lab Manager

May 22, 2025

May 22, 2025

Is Wall Street Bullish or Bearish on Revvity Stock? - inkl

May 22, 2025

May 22, 2025

Is Wall Street Bullish Or Bearish On Revvity Stock? - Barchart.com

May 22, 2025

May 22, 2025

Revvity (RVTY) Receives Affirmed Buy Rating with Promising Outlo - GuruFocus

May 22, 2025

May 22, 2025

Revvity (RVTY) Receives Affirmed Buy Rating with Promising Outlook | RVTY Stock News - GuruFocus

May 22, 2025

May 21, 2025

Sustainable chemistry in India fueling growth with digital and AI innovation: Revvity Signals - Indian Chemical News

May 21, 2025

May 20, 2025

Revvity announces launch of new fully automated instrument for specialty testing - BioSpectrum India

May 20, 2025

May 19, 2025

Revvity's EUROIMMUN Unveils New Fully Automated Instrument for S - GuruFocus

May 19, 2025

May 19, 2025

Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing | RVTY Stock News - GuruFocus

May 19, 2025

May 19, 2025

Revvity’s EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing - Business Wire

May 19, 2025

May 19, 2025

Revvity's New Automated Platform Transforms Specialty Disease Testing with 20-Analyte Capability - Stock Titan

May 19, 2025

May 16, 2025

Revvity Inc. stock outperforms competitors on strong trading day - MarketWatch

May 16, 2025

May 14, 2025

Revvity Signals Software Inc. v. Cloud Software Group Inc. - Cornerstone Research

May 14, 2025

May 14, 2025

Revvity Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

May 14, 2025

May 14, 2025

Global Preeclampsia Diagnostics Market to Exhibit Growth at a CAGR of ~4% by 2032 | DelveInsight - GlobeNewswire Inc.

May 14, 2025

May 14, 2025

Shareholders Will Be Pleased With The Quality of Revvity's (NYSE:RVTY) Earnings - Yahoo

May 14, 2025

May 13, 2025

Revvity at Bank of America 2025 Healthcare Conference: Navigating Tariffs and Growth - Investing.com India

May 13, 2025

May 13, 2025

Revvity To Present At Bank Of America Global Healthcare Conference 2025; Webcast At 12:20 PM ET - Nasdaq

May 13, 2025

May 12, 2025

Revvity beats quarterly estimates on steady demand for medical equipment - MSN

May 12, 2025

May 12, 2025

Repligen, Bruker, Agilent, Medpace, and Revvity Shares Skyrocket, What You Need To Know - Yahoo Finance

May 12, 2025

May 12, 2025

RVTY Q1 Earnings Call: Resilient Performance Amid Academic and Tariff Headwinds, Software and Diagnostics Shine - Yahoo Finance

May 12, 2025

May 09, 2025

Revvity: Despite Facing Multiple Headwinds, Shares Are A Buy (NYSE:RVTY) - Seeking Alpha

May 09, 2025

May 07, 2025

High Content Screening Market Global Forecasts 2025-2030 - GlobeNewswire

May 07, 2025

May 07, 2025

High Content Screening Market Global Forecasts 2025-2030 with Danaher, Revvity, BD, Carl Zeiss, Merck, and Thermo Fisher Scientific Dominating the $2.19 Billion Market - Yahoo Finance

May 07, 2025

May 06, 2025

Revvity joins peers Thermo Fisher, Danaher in tariff warning, maintains profit outlook - MSN

May 06, 2025

May 05, 2025

Revvity Announces Financial Results for the First Quarter of 2025 - ADVFN

May 05, 2025

May 02, 2025

UBS Upgrades Revvity (BMV:RVTY) - Nasdaq

May 02, 2025

May 02, 2025

UBS Upgrades Revvity (BIT:1RVTY) - Nasdaq

May 02, 2025

May 02, 2025

UBS lifts Revvity stock rating to Buy, cuts price target to $115 - Investing.com Australia

May 02, 2025

May 02, 2025

UBS Upgrades Revvity (LSE:0KHE) - Nasdaq

May 02, 2025

May 01, 2025

UBS Upgrades Revvity (RVTY) - Nasdaq

May 01, 2025

May 01, 2025

UBS Boosts Revvity (RVTY) Rating to Buy Amid Growth Prospects | - GuruFocus

May 01, 2025

May 01, 2025

UBS lifts Revvity stock rating to Buy, cuts price target to $115 By Investing.com - Investing.com South Africa

May 01, 2025

May 01, 2025

UBS Upgrades Revvity to Buy from Neutral, Cuts Price Target to $115 From $145 - marketscreener.com

May 01, 2025

May 01, 2025

UBS Boosts Revvity (RVTY) Rating to Buy Amid Growth Prospects | RVTY Stock News - GuruFocus

May 01, 2025

Apr 30, 2025

Revvity to Present at Upcoming Investor Conferences | RVTY Stock News - GuruFocus

Apr 30, 2025

Apr 30, 2025

KeyBanc Adjusts Revvity's Price Target to $135 From $145 - marketscreener.com

Apr 30, 2025

Apr 30, 2025

Revvity CEO and CFO to Share Strategic Vision at BofA and Goldman Sachs Healthcare Conferences - Stock Titan

Apr 30, 2025

Apr 30, 2025

Revvity Reports Strong Q1 2025 Financial Results - TipRanks

Apr 30, 2025

Apr 29, 2025

Revvity reaffirms 2025 guidance with $4.90-$5 EPS target amid robust software growth - MSN

Apr 29, 2025

Apr 29, 2025

Stifel maintains Revvity stock Hold rating, $120 target By Investing.com - Investing.com Canada

Apr 29, 2025